Glucagonoma medical therapy

Revision as of 18:30, 1 August 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma medical therapy

CDC on Glucagonoma medical therapy

Glucagonoma medical therapy in the news

Blogs on Glucagonoma medical therapy

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

The predominant therapy for glucagonoma is surgical resection. Adjunctive chemotherapy may be required.

Medical Therapy

Management of primary tumor

  • Somatostatin analogs (octreotide) are the treatment of choice to control symptoms. 36
  • Doxorubicin and streptozotocin have also been used successfully to selectively damage alpha cells of the pancreatic islets.

Metastasis therapy

Hepatic artery embolization 

  • Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Embolization can be performed via the infusion through an angiography catheter into hepatic arteries Gelfoam powder in conjunction with chemotherapy radioactive isotopes. 59

Radiofrequency ablation

  • Ablation can be performed percutaneously or laparoscopically technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Ablation is applicable only to smaller lesions less than 3 cm

Molecularly therapy 

  • Molecularly targeted agents everolimus, sunitinib have a role in the management of patients with progressive advanced glucagonomas who are not symptomatic from tumor bulk or have rapidly progressive metastatic peptide receptor radioligand therapy with radiolabeled somatostatin analogs

Cytotoxic chemotherapy 

  • Peptide receptor radioligand therapy with radiolabeled somatostatin analogs

References


Template:WikiDoc Sources